AOP ORPHAN AND CHORD ANNOUNCE A PARTNERSHIP TO DEVELOP CRD1 (CLADRIBINE) FOR TREATMENT OF ORPHAN AUTOIMMUNE DISEASES
Vienna and Geneva (pts017/03.01.2019/15:00) – AOP Orphan Pharmaceuticals AG (AOP Orphan) and Chord Therapeutics (Chord) step into a new partnership to develop CRD1 for treatment of orphan autoimmune diseases. CDR1 is a new formulation of cladribine, an immunosuppressant with promising activity against autoimmune diseases. Autoimmune neurological diseases are a family of severe disorders that result … Skaityti toliau